Affinia Therapeutics has received the US Food and Drug Administration (FDA) fast track designation (FTD) for AFTX-201, a ...

The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.

Johnson & Johnson has won U.S. Food and Drug Administration fast-track designation for its investigational nipocalimab drug in adults with systemic lupus erythematosus, a chronic autoimmune disease.

AFTX-201 is designed using Affinia's proprietary capsid engineered for efficient cardiac transduction at doses that are 5-10-fold lower than doses of gene therapies using conventional capsids WALTHAM, ...

FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...

The FDA has granted Fast Track Designation to AKY-1189 (actinium-225; 225 Ac) a potent alpha-emitting radioisotope in the ...

Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...

The FDA has granted Fast Track designation to AFTX-201 for the treatment of BAG3-associated dilated cardiomyopathy.

FDA granted fast track designation to AKY-1189 for adults with metastatic urothelial cancer after systemic therapy, aiming to ...

Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported ...

The objective is seamless connectivity from Badlapur and Ambarnath to Thane, Navi Mumbai and Mumbai. These expansions will ...

UK Defence Innovation (UKDI) has launched Phase 3 (Cycle 7) of Innovation Support to Operations - looking for tech that can be developed fast and ...